Baillie Gifford & Co. Has $917.60 Million Stake in Elevance Health, Inc. (NYSE:ELV)

Baillie Gifford & Co. reduced its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,487,384 shares of the company's stock after selling 282,184 shares during the period. Baillie Gifford & Co. owned approximately 1.07% of Elevance Health worth $917,596,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of ELV. Raelipskie Partnership acquired a new stake in Elevance Health during the 3rd quarter worth approximately $26,000. PSI Advisors LLC acquired a new stake in shares of Elevance Health in the third quarter valued at approximately $27,000. Eastern Bank acquired a new stake in shares of Elevance Health in the third quarter valued at approximately $31,000. Crews Bank & Trust acquired a new stake in shares of Elevance Health in the fourth quarter valued at approximately $34,000. Finally, Dunhill Financial LLC raised its holdings in shares of Elevance Health by 57.8% in the third quarter. Dunhill Financial LLC now owns 71 shares of the company's stock valued at $37,000 after purchasing an additional 26 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Price Performance

ELV traded down $0.98 on Thursday, hitting $390.73. 1,324,897 shares of the stock were exchanged, compared to its average volume of 1,618,045. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26. The business has a 50-day moving average of $384.93 and a two-hundred day moving average of $445.67. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. The firm has a market capitalization of $90.62 billion, a price-to-earnings ratio of 15.26, a PEG ratio of 1.15 and a beta of 0.83.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. Sell-side analysts forecast that Elevance Health, Inc. will post 34 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be given a dividend of $1.71 per share. This is a boost from Elevance Health's previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 annualized dividend and a yield of 1.75%. Elevance Health's dividend payout ratio is currently 25.46%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Elevance Health from $501.00 to $512.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Stephens downgraded shares of Elevance Health from an "overweight" rating to an "equal weight" rating and lowered their target price for the stock from $520.00 to $440.00 in a report on Wednesday, January 22nd. Morgan Stanley lowered their target price on shares of Elevance Health from $643.00 to $551.00 and set an "overweight" rating on the stock in a report on Wednesday, October 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $485.00 target price on shares of Elevance Health in a report on Friday, January 24th. Finally, StockNews.com upgraded shares of Elevance Health from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Elevance Health presently has an average rating of "Moderate Buy" and an average price target of $517.03.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.